SAN DIEGO, Jul 19, 2010 (BUSINESS WIRE) --
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its Cancer
Immunotherapy Index has appreciated 50.04% during the twelve months
since its creation on July 10, 2009. This rate of gain is 339% of the
average gain of the Dow Jones Industrials (15.48%), S&P 500 (13.24%) and
NASDAQ Composite (15.50%) during the similar four quarter period.
The equally weighted Cancer Immunotherapy Index is regularly benchmarked
against the appreciation of the average of the NASDAQ, S&P, and NYSE
Biotech Indices. For the last 52 week period the biotech indices
averaged a 28.01% gain. In comparison, the Cancer Immunotherapy Index
50.04% gain was appreciating at 179% of the overall biotech average.
The Mentor Capital Cancer Immunotherapy Index companies and their
reported one-year gain since Index formation July 10, 2009 follow:
Dendreon
(DNDN) +42.63%, Immunocellular Therapeutics, Ltd.
(IMUC) +243.33%, Oncothyreon
(ONTY) +8.33%, Antigenics
(AGEN) -50.33%, Biovest International (BVTI.PK) +282.86%, Celldex
Therapeutics
(CLDX) -32.39%, Northwest Biotherapeutics
(NWBO) -10.67%, CEL -- SCI Corp.
(CVM) +22.50% and Generex
Biotechnology
(GNBT) -38.18% as a proxy for its wholly-owned
immunotherapeutic subsidiary, Antigen Express, Quantum Immunologics,
Inc. +33.33% a private company, and Provectus Pharmaceuticals, Inc.
(PVCT) +5.77% since it was added to the Index February 22, 2009 -
all for an average one-year gain of 50.04%.
Mentor Capital, Inc., by acquisition or stock purchase, seeks to invests
in all companies in the Cancer Immunotherapy Index or likely candidates
for Index inclusion. In this sector Mentor Capital management attempts
to significantly overweight its positions in those companies it views
with the greatest medical and financial promise. The Index company
summaries can be tracked through updates of the Cancer Immunotherapy
Index presented at
.
Forward Looking Statements, Safe Harbor and Risk Descriptions are
Incorporated by Reference from the MNTR Company Web Site above.
SOURCE: Mentor Capital, Inc.
Mentor Capital, Inc.
Chet Billingsley, CEO
760-788-4700
Copyright Business Wire 2010